Efficacy of fesoterodine fumarate in Neurogenic Detrusor Overactivity (NDO) due to Spinal Cord Lesion (SCL) or Multiple Sclerosis (MS) – A prospective study

You have accessJournal of UrologyLate-breaking Abstract I - Benign1 Sep 2021LBA01-07 EFFICACY OF FESOTERODINE FUMARATE IN NEUROGENIC DETRUSOR OVERACTIVITY DUE TO SPINAL CORD LESION OR MULTIPLE SCLEROSIS – A PROSPECTIVE STUDY Charalampos Konstantinidis, Michael Samarinas, Charalampos Thomas, Moira Tzitzika, Konstantinos Giannitsas, and Anastasios Athanasopoulos Charalampos KonstantinidisCharalampos Konstantinidis More articles by this author , Michael SamarinasMichael Samarinas More articles by this author , Charalampos ThomasCharalampos Thomas More articles by this author , Moira TzitzikaMoira Tzitzika More articles by this author , Konstantinos GiannitsasKonstantinos Giannitsas More articles by this author , and Anastasios AthanasopoulosAnastasios Athanasopoulos More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002148.07AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Antimuscarinic drugs are the first-line choice in the treatment of patients with neurogenic Detrusor Overactivity (nDO). Fesoterodine fumarate is the newest antimuscarinic drug. Limited data are published about the use of Fesoterodine fumarate in patients suffering from Neurogenic Lower Urinary Tract Dysfunction (NLUTD). Our study aims to determine the efficacy of Fesoterodine fumarate on patients with nDO due to Spinal Cord Lesion (SCL) or Multiple sclerosis (MS) METHODS: This is an open-label prospective interventional study. Eligible patients were 18-80 years old with SCL or MS and nDO confirmed by a urodynamic study (UDS). At baseline, patients underwent a UDS to confirm nDO. Quality of life (QoL) was assessed by the SF (Short-Form) Qualiveen questionnaire. Patients received fesoterodine 8 mg/d for 3 months and were re-evaluated with UDS and SF-Qualiveen. The primary endpoint was the confirmation of the maximum detrusor pressure (Pdetmax) reduction after treatment. Secondary endpoints were the evaluation of maximum bladder capacity and compliance and the effect on QoL. Statistical analysis performed by Wilcoxon-test using SPSSv26. RESULTS: 124 patients completed the study. 95 of them (76.6%) had SCL, while 29 (23.4%) had MS. Pdetmax had a significant reduction, while bladder capacity and compliance were improved after treatment in the whole and individual subgroups (p <0.001). SF-Qualiveen revealed a significant increase (p <0.001) in QoL in the whole group and each subgroup. CONCLUSIONS: Fesoterodine fumarate is effective against NDO in favour of Upper Urinary Tract protection for patients with Spinal Cord Lesion or Multiple Sclerosis, improving the urodynamic parameters and QoL, independently of the underlying neurological disease. Source of Funding: None © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e1173-e1173 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Charalampos Konstantinidis More articles by this author Michael Samarinas More articles by this author Charalampos Thomas More articles by this author Moira Tzitzika More articles by this author Konstantinos Giannitsas More articles by this author Anastasios Athanasopoulos More articles by this author Expand All Advertisement Loading ...